Xeris Biopharma Holdings Inc
LSE:0A8E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Xeris Biopharma Holdings Inc
LSE:0A8E
|
US |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
US |
|
State Bank of India
NSE:SBIN
|
IN |
|
L
|
Lenzing AG
SWB:LEN
|
AT |
|
Portillos Inc
NASDAQ:PTLO
|
US |
|
H
|
Hershey Co
XMUN:HSY
|
US |
|
Svenska Cellulosa SCA AB
OTC:SVCBF
|
SE |
|
D
|
Dover Corp
DUS:DOV
|
US |
|
S
|
Singapore Telecommunications Ltd
SWB:SIT4
|
SG |
|
Entertainment Network (India) Ltd
BSE:532700
|
IN |
Wall St Price Targets
0A8E Price Targets Summary
Xeris Biopharma Holdings Inc
According to Wall Street analysts, the average 1-year price target for 0A8E is 11.41 USD with a low forecast of 8.11 USD and a high forecast of 18.98 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0A8E's stock price target?
Price Target
11.41
USD
According to Wall Street analysts, the average 1-year price target for 0A8E is 11.41 USD with a low forecast of 8.11 USD and a high forecast of 18.98 USD.
What is the Revenue forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
10%
Over the last 8 years, the compound annual growth rate for Revenue has been 92%. The projected CAGR for the next 7 years is 10%.
What is the Operating Income forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
62%
The compound annual growth rate for Operating Income over the next 5 years is 62%.
What is the Net Income forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
462%
The compound annual growth rate for Net Income over the next 3 years is 462%.
